Literature DB >> 23711330

High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center.

Marjolaine Morgand1, Marc Buffet, Marc Busson, Pascale Loiseau, Sandrine Malot, Kahina Amokrane, Catherine Fortier, Jonathan London, Guy Bonmarchand, Alain Wynckel, François Provôt, Pascale Poullin, Philippe Vanhille, Claire Presne, Dominique Bordessoule, Stéphane Girault, Yahsou Delmas, Mohamed Hamidou, Christiane Mousson, Cécile Vigneau, Alexandre Lautrette, Jacques Pourrat, Lionel Galicier, Elie Azoulay, Frédéric Pène, Jean-Paul Mira, Eric Rondeau, Mario Ojeda-Uribe, Dominique Charron, Eric Maury, Bertrand Guidet, Agnès Veyradier, Ryad Tamouza, Paul Coppo.   

Abstract

BACKGROUND: Infectious events have been reported as major environmental triggers of thrombotic thrombocytopenic purpura (TTP). We detail here the potential association between infections and TTP. STUDY DESIGN AND METHODS: We recruited randomly and prospectively a cohort of 280 consecutive TTP patients during a 9-year period. Features of infection were systematically recorded.
RESULTS: Features consistent with an infectious event were observed in 114 patients (41%) at time of TTP diagnosis. Infectious agents were documented in 34 cases and were mainly Gram-negative bacilli. At time of diagnosis infected patients more frequently had fever (p < 0.001). Infections at diagnosis did not impact prognosis and outcome. Thirty-six percent of patients experienced an infectious event during hospitalization, which resulted in more exacerbation of TTP (p = 0.02). Infections were not overrepresented during treatment in patients who received steroids and/or rituximab. Further genetic analysis of toll-like receptor (TLR)-9 functionally relevant polymorphisms revealed that TLR-9 +2848 G and TLR-9 +1174 A genotypes were more frequent in TTP patients than in controls (p = 0.04 and p = 0.026, respectively) and more particularly in patients negative for the Class II human leukocyte antigen system susceptibility allele DRB1*11 (p = 0.001 and p = 0.002, respectively). Haplotypes estimation showed that 1174A-2848G haplotype was significantly more frequent in TTP (p = 0.004), suggesting a primary role for this haplotype variation in conferring a predisposition for acquired TTP.
CONCLUSION: Infections should be considered as an aggravating factor during the course of TTP. Particular polymorphisms in TLR-9 gene may represent risk factors for TTP.
© 2013 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23711330     DOI: 10.1111/trf.12263

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  10 in total

Review 1.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2017-08-02       Impact factor: 22.113

2.  Infection in Patients with Suspected Thrombotic Microangiopathy Based on Clinical Presentation.

Authors:  Benjamin Thoreau; Florent von Tokarski; Adeline Bauvois; Guillaume Bayer; Christelle Barbet; Sylvie Cloarec; Elodie Mérieau; Sébastien Lachot; Denis Garot; Louis Bernard; Emmanuel Gyan; Franck Perrotin; Claire Pouplard; François Maillot; Philippe Gatault; Bénédicte Sautenet; Emmanuel Rusch; Véronique Frémeaux-Bacchi; Cécile Vigneau; Fadi Fakhouri; Jean-Michel Halimi
Journal:  Clin J Am Soc Nephrol       Date:  2021-09       Impact factor: 10.614

3.  Dengue Virus Infection Triggering Thrombotic Thrombocytopenic Purpura in Pregnancy.

Authors:  Surendran Deepanjali; Raghuramulu R Naik; Sharada Mailankody; Sivamani Kalaimani; Tamilarasu Kadhiravan
Journal:  Am J Trop Med Hyg       Date:  2015-08-17       Impact factor: 2.345

4.  Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis.

Authors:  Flora Peyvandi; Spero Cataland; Marie Scully; Paul Coppo; Paul Knoebl; Johanna A Kremer Hovinga; Ara Metjian; Javier de la Rubia; Katerina Pavenski; Jessica Minkue Mi Edou; Hilde De Winter; Filip Callewaert
Journal:  Blood Adv       Date:  2021-04-27

Review 5.  Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers.

Authors:  Johana Hrdinová; Silvia D'Angelo; Nuno A G Graça; Bogac Ercig; Karen Vanhoorelbeke; Agnès Veyradier; Jan Voorberg; Paul Coppo
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

6.  Upshaw-Schulman syndrome-associated ADAMTS13 variants possess proteolytic activity at the surface of endothelial cells and in simulated circulation.

Authors:  Anton Letzer; Katja Lehmann; Christian Mess; Gesa König; Tobias Obser; Sven Peine; Sonja Schneppenheim; Ulrich Budde; Stefan W Schneider; Reinhard Schneppenheim; Maria A Brehm
Journal:  PLoS One       Date:  2020-05-04       Impact factor: 3.240

7.  Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.

Authors:  Paul Knoebl; Spero Cataland; Flora Peyvandi; Paul Coppo; Marie Scully; Johanna A Kremer Hovinga; Ara Metjian; Javier de la Rubia; Katerina Pavenski; Jessica Minkue Mi Edou; Hilde De Winter; Filip Callewaert
Journal:  J Thromb Haemost       Date:  2019-12-09       Impact factor: 5.824

8.  Diagnosis and follow-up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay.

Authors:  Nicolas Beranger; Sandrine Benghezal; Bérangère S Joly; Sophie Capdenat; Adeline Delton; Alain Stepanian; Paul Coppo; Agnès Veyradier
Journal:  Res Pract Thromb Haemost       Date:  2020-12-15

Review 9.  Emerging Concepts in Immune Thrombotic Thrombocytopenic Purpura.

Authors:  Aicha Laghmouchi; Nuno A G Graça; Jan Voorberg
Journal:  Front Immunol       Date:  2021-11-11       Impact factor: 7.561

10.  Marked Improvement in Refractory TTP Directly after H. pylori Eradication Therapy.

Authors:  Irina Gringauz; Narin Nard Carmel-Neiderman; Tobin Mangel; Orith Portnoy; Gad Segal; Idan Goren
Journal:  Case Rep Hematol       Date:  2016-04-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.